Arthur D. Little analysis shows that companies moving early on first-in-class oncology assets can secure a dominant share of the market soon after launch, with the opportunity diminishing rapidly thereafter. In an era of tighter budgets and higher scrutiny, applying rigorous due diligence to clinical trial design is critical to accelerating timelines, strengthening ROI, and capturing value before it slips away. Explore our latest Viewpoint for a closer look: https://lnkd.in/ePiT96HJ ...

Arthur D. Little

Biopharma pours vast sums of money into clinical trials, yet many still rely more on optimism than evidence, while private equity approaches comparable risks with relentless, data-led discipline. Applying that same rigorous mindset to trial design and oversight can sharpen decisions, reduce risk, accelerate timelines, and materially improve R&D returns. It’s time to stop betting on hope and start running clinical trials like the investments they are. ADL’s newest Viewpoint explores this in more ...

Arthur D. Little

Are clinical trials treated with the same rigor as other high-stakes investments? Clinical trials aren’t solely scientific projects; they are also investment decisions. Trials, especially Phase II and Phase III, are among the most capital-intensive bets a biopharma company can make, yet many still advance on internal optimism rather than external validation. In contrast, private equity firms apply structured due diligence to every major decision by testing assumptions, quantifying risk, and grou ...

Arthur D. Little